semaglutide first‑line obesity

ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity — Photo by SHVETS production on Pexels

35% of PCPs Let Coverage Denials Block Semaglutide

35% of primary care physicians report that insurance denials block semaglutide prescriptions for their obesity patients. These denials keep many eligible adults from receiving a first-line therapy that can lower BMI by more than four points in a year. Medical Disclaimer: This article is for informational purposes only and does